Novo Nordisk Sues Eli Lilly Over Alleged Misleading Weight Loss Drug Advertising
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging that advertisements for Zepbound and Mounjaro mislead consumers by using outdated data to suggest superior effectiveness compared to Novo's drugs. The suit seeks an injunction halting these ads and financial damages.
Topics: Misleading Advertising Pharmaceuticals Weight Loss Drugs